What the RECONNECT Bremelanotide Trials Studied

The RECONNECT bremelanotide program consisted of two similarly designed Phase 3 clinical trials that studied a defined 1.75 mg subcutaneous bremelanotide formulation administered as needed in premenopausal women who met protocol criteria for acquired, generalized hypoactive sexual desire disorder. The trials compared bremelanotide with placebo over a 24-week double-blind treatment period and evaluated prespecified measures of sexual desire, distress associated with low desire, safety, tolerability, study completion, and product use.

The RECONNECT trials form one part of the clinical-development record discussed in PT-141 peptide research. Their findings should be interpreted according to the exact bremelanotide product, subcutaneous route, selected study population, endpoint definitions, administration instructions, and observation period used in the protocols.

This article is provided for general educational purposes and explains clinical-study design and evidence-interpretation concepts associated with PT-141 and bremelanotide research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

RECONNECT did not study every material described online as PT-141, every injection schedule, every sexual-function concern, every age group, or every population in which low desire may be reported.

What Does RECONNECT Refer To?

RECONNECT is the name used for two pivotal bremelanotide studies conducted as part of the later clinical-development program.

The trials were commonly identified as:

• Study 301
• Study 302
• NCT02333071
• NCT02338960

The two studies were designed to provide separate and integrated evidence under closely aligned protocols.

Why Two Phase 3 Trials Were Conducted

Conducting two similarly designed trials allows researchers and regulators to examine whether findings are reproduced in separate participant groups.

Replication can help evaluate:

• consistency of the direction of findings
• similarity of endpoint behavior
• variation between studies
• adverse-event patterns
• study completion
• robustness of the overall evidence

Two trials do not eliminate uncertainty, but they provide more information than one isolated study.

The Trials Were Phase 3 Studies

Phase 3 trials are generally designed to evaluate prespecified outcomes and safety in a larger population after earlier development has informed the product, route, amount, and endpoint strategy.

The RECONNECT program followed earlier research involving:

• initial human exposure
• intranasal PT-141 formulations
• subcutaneous administration
• pharmacokinetics
• dose-ranging
• endpoint selection

The Phase 3 design should not be interpreted as interchangeable with those earlier studies.

The Exact Study Product

The pivotal trials evaluated a defined bremelanotide formulation rather than an unidentified material carrying the PT-141 name.

Product-specific variables included:

• bremelanotide as the active ingredient
• a fixed 1.75 mg amount
• a defined injection volume
• subcutaneous administration
• a study delivery device
• controlled manufacturing and storage

The results do not automatically characterize separately sourced or differently formulated products.

Subcutaneous Administration

Participants administered the study product by subcutaneous injection.

This route places the formulation into tissue beneath the skin and differs from:

• intranasal administration
• intramuscular injection
• intravenous administration
• oral administration
• other local routes

Evidence from RECONNECT should remain tied to the subcutaneous formulation used in the trials.

As-Needed Administration

The study product was used on an as-needed basis rather than as a fixed daily treatment.

An as-needed protocol requires attention to:

• when an injection was administered
• the interval before anticipated sexual activity
• the number of administrations
• the number of evaluable events
• adherence to maximum-use instructions
• diary completion

Participants did not necessarily receive the same number of injections during the study.

The 1.75 mg Study Amount

The pivotal program evaluated the amount selected after earlier dose-ranging development.

The choice reflected consideration of:

• earlier outcome measurements
• pharmacokinetic evidence
• blood-pressure observations
• nausea and tolerability
• discontinuation patterns
• feasibility of as-needed use

Selection for Phase 3 study does not mean the amount is appropriate for every person or every product.

The 24-Week Double-Blind Period

Participants were assigned to 24 weeks of blinded treatment with bremelanotide or placebo.

This period allowed researchers to examine:

• change from baseline
• repeated as-needed administration
• questionnaire outcomes
• adverse events
• study discontinuation
• use patterns over several months

The core findings should not be extended beyond the studied duration without additional evidence.

Randomized Assignment

Eligible participants were assigned randomly to bremelanotide or placebo.

Randomization is intended to reduce systematic differences involving:

• baseline desire scores
• baseline distress
• condition duration
• expectations
• relationship characteristics
• other measured and unmeasured variables

Chance imbalances may still occur and should be considered in the statistical analysis.

Placebo Control

The placebo group provided a comparison for changes that may occur during trial participation without active bremelanotide exposure.

Such changes may reflect:

• expectation
• increased attention to sexual experiences
• diary completion
• relationship changes
• natural variation
• regression toward the mean

The main interpretation concerns differences between assigned groups, not only changes within the bremelanotide group.

Double Blinding

Participants and designated study personnel generally remained unaware of treatment assignment during the controlled period.

Blinding may reduce bias in:

• questionnaire responses
• event reporting
• investigator interactions
• outcome assessment
• study retention decisions

Recognizable adverse events may still allow some participants to infer their assignment.

Multicenter Design

RECONNECT was conducted across multiple research centers.

A multicenter design can provide:

• a larger participant pool
• geographic diversity
• experience across different investigators
• information about protocol reproducibility

It can also introduce variation in recruitment, participant counseling, and study-site procedures.

The Target Study Population

The pivotal trials focused on premenopausal women with acquired, generalized hypoactive sexual desire disorder.

This population definition included several distinct elements:

• premenopausal status
• low sexual desire
• associated distress
• an acquired rather than lifelong pattern
• a generalized rather than situation-specific pattern
• absence of specified alternative explanations

Each element narrowed the population to which the results apply most directly.

What Acquired Means

Acquired HSDD refers to low desire that developed after a period in which the participant did not report the same problem.

This differs from a lifelong pattern present throughout the person’s sexual history.

A trial restricted to acquired HSDD does not provide direct evidence for lifelong low desire.

What Generalized Means

Generalized HSDD refers to low desire that is not limited to one partner, one type of activity, or one situation.

This differs from a situational pattern that may occur only under particular circumstances.

Results in a generalized population should not automatically be assigned to relationship-specific or situation-specific concerns.

Distress Was Part of the Condition Definition

Low desire alone was not treated as sufficient for the pivotal study population.

The condition also involved associated personal distress or interpersonal difficulty under the applicable diagnostic and protocol framework.

This matters because:

• desire and distress are separate concepts
• low desire without distress may not meet the same definition
• distress can be affected by personal and relationship context
• each concept requires its own measurement method

Alternative Explanations Were Considered

Eligibility procedures were intended to distinguish the study condition from low desire primarily attributable to other causes.

Potential alternative explanations could include:

• another medical condition
• a psychiatric condition
• medication or substance effects
• significant relationship problems
• temporary life circumstances
• another sexual-function condition

Excluding selected causes improves specificity but reduces generalizability.

Relationship Requirements

The trials included protocol requirements related to a stable relationship context.

Such requirements can support consistent event and diary interpretation, but they may exclude:

• people without a current partner
• people in newly formed relationships
• people with substantial relationship conflict
• people whose sexual experiences occur in another context

The evidence should not be generalized beyond the relationship context studied without qualification.

Screening and Baseline Assessment

Before randomization, potential participants underwent screening and baseline evaluation.

This process could include:

• medical history
• diagnostic assessment
• medication review
• questionnaire completion
• electronic diary use
• laboratory or vital-sign assessment
• confirmation of eligibility

Participants who did not meet the protocol requirements did not enter the randomized trial.

The Desire Endpoint

One co-primary endpoint measured sexual desire using a defined domain of a validated questionnaire.

The endpoint was not simply a yes-or-no report of whether a participant felt different.

Interpretation required attention to:

• the questionnaire used
• the scoring range
• the recall period
• baseline score
• change during treatment
• difference from placebo

The Distress Endpoint

The other co-primary endpoint measured distress associated with low sexual desire.

This endpoint examined how frequently or strongly participants reported being bothered by low desire under the selected instrument.

It did not measure every form of:

• general emotional distress
• relationship satisfaction
• anxiety
• depression
• overall quality of life

The finding should remain limited to the defined desire-related distress item or scale.

Why the Endpoints Were Co-Primary

Using co-primary endpoints reflects the importance of evaluating both low desire and associated distress.

Depending on the statistical plan, success may require:

• a supported difference on both endpoints
• prespecified handling of multiple tests
• consistent results across the trials
• acceptable missing-data assumptions

One favorable endpoint should not automatically replace the complete co-primary framework.

Satisfying Sexual Events

The trials also collected information about satisfying sexual events.

This endpoint involved different concepts from questionnaire-based desire and distress.

Interpretation required definition of:

• what counted as an event
• how satisfaction was reported
• the relevant diary interval
• how events were linked to product use
• how periods with no events were handled

Event frequency should not be treated as identical to sexual desire.

Electronic Diary Data

Electronic diaries were used to collect information during the study.

Diary data can reduce long recall periods, but they depend on:

• participant completion
• timing of entries
• understanding of questions
• technical access
• honest and consistent reporting
• handling of missed entries

Diary adherence is part of the reliability of the endpoint.

Participant-Reported Outcomes

The pivotal outcomes relied substantially on participant reports because desire and distress are subjective experiences.

Participant-reported outcomes can be scientifically appropriate when:

• the concept is inherently personal
• the instrument is validated
• the questions are clearly defined
• the recall period is appropriate
• the analysis is prespecified

Subjective does not mean meaningless, but it requires careful study design.

Outcome Change and Clinical Meaning

A statistically supported average difference does not by itself show what the change meant to each participant.

Clinical interpretation may also consider:

• absolute score change
• confidence intervals
• responder thresholds
• participant global assessments
• individual variation
• consistency across instruments

Different approaches to meaningful change can produce different responder estimates.

Safety Was a Major Trial Component

RECONNECT also examined adverse events and physiological observations during repeated as-needed use.

Safety evaluation included categories such as:

• treatment-emergent adverse events
• serious adverse events
• events leading to discontinuation
• nausea
• flushing
• headache
• injection-site observations
• blood-pressure measurements

Event frequency must be interpreted with the study population and duration.

Nausea and Trial Completion

Nausea was an important tolerability observation in the development program.

Interpretation may consider:

• frequency after initial use
• severity
• duration
• recurrence
• relationship to discontinuation
• change with subsequent administrations

A common event may materially affect use even when most reports are not classified as serious.

Blood-Pressure Observations

Blood pressure was monitored because transient increases were observed after bremelanotide administration.

Relevant interpretation includes:

• timing after injection
• average change
• individual maximum changes
• duration
• baseline cardiovascular status
• participant exclusions

Results in a screened population do not describe every cardiovascular-risk group.

Discontinuation Is Part of the Evidence

Trial interpretation should include how many participants stopped treatment or left the study.

Reasons may include:

• adverse events
• withdrawal of consent
• loss to follow-up
• protocol deviations
• pregnancy
• other personal reasons

An analysis limited to participants who completed the study can differ from an analysis including all randomized participants.

Missing Data

Missing questionnaire, diary, or follow-up data can influence estimated treatment differences.

Researchers may use:

• model-based methods
• multiple imputation
• sensitivity analyses
• defined assumptions about discontinuation
• alternative analysis populations

Interpretation depends on whether conclusions remain similar under reasonable assumptions.

Integrated and Individual Study Analyses

Results may be reported for each trial separately and for the combined population.

Integrated analysis can:

• increase precision
• provide a larger safety denominator
• support subgroup exploration
• summarize consistency

It should not conceal meaningful differences between the individual trials.

Subgroup Analyses

Researchers may examine results across prespecified participant subgroups.

Subgroups may involve:

• age
• baseline severity
• hormonal contraceptive use
• condition duration
• coexisting arousal concerns
• other baseline characteristics

Many subgroup analyses have limited statistical power and should not be treated as separate confirmatory trials.

The Open-Label Extension

Participants completing the double-blind phase could be eligible for a longer open-label extension.

The extension examined:

• longer exposure
• continued adverse-event monitoring
• participant retention
• continued questionnaire measurements
• discontinuation over time

Because all extension participants received active treatment and knew that they were doing so, interpretation differs from the placebo-controlled core period.

Extension-Study Selection

Not every randomized participant entered the extension.

Eligibility and participation could be influenced by:

• completion of the core study
• earlier tolerability
• willingness to continue
• perceived experience
• study-site availability

This selection can produce a population different from the original randomized group.

What RECONNECT Did Not Study

The pivotal trials did not directly study:

• postmenopausal women as the indicated population
• men as the indicated population
• children
• lifelong HSDD
• situational low desire
• low desire primarily caused by medication
• relationship conflict as the primary explanation
• every psychiatric or medical comorbidity

These exclusions limit generalization.

RECONNECT Did Not Compare Every Alternative

The trials compared bremelanotide with placebo rather than with every other intervention or management approach.

They therefore did not directly establish:

• superiority over another approved drug
• superiority over psychotherapy
• superiority over relationship-based interventions
• equivalence to another formulation
• comparative cost-effectiveness

Cross-study comparisons cannot replace a head-to-head trial.

RECONNECT and Unidentified PT-141 Products

The pivotal findings concerned the characterized product used in the development program.

They do not establish that an unrelated product sold as PT-141 has the same:

• sequence identity
• purity
• concentration
• sterility
• formulation
• stability
• delivery performance

A shared name is not evidence of pharmaceutical equivalence.

What the RECONNECT Trials Can Establish

The trials can provide evidence about:

• the defined 1.75 mg subcutaneous product
• as-needed administration under the protocol
• prespecified desire and distress endpoints
• placebo-adjusted findings in the selected population
• adverse events during the study period
• discontinuation and adherence
• consistency across two pivotal trials

The conclusions remain tied to those conditions.

What the RECONNECT Trials Do Not Automatically Establish

The trials do not automatically establish:

• the same findings for every PT-141 product
• the same findings in postmenopausal women
• the same findings in men
• results for lifelong or situational low desire
• superiority over untested alternatives
• long-term safety beyond available follow-up
• suitability for a particular person

Reading the RECONNECT Evidence

Readers may ask:

• Which of the two trials is being discussed?
• Was the analysis individual or integrated?
• Which endpoint was measured?
• Was the finding prespecified?
• How large was the placebo-adjusted difference?
• How were missing data handled?
• What adverse events and discontinuations occurred?
• Does the population match the claim being made?

The ClinicalTrials.gov record for RECONNECT Study 302 describes the randomized, double-blind, placebo-controlled design, intervention, eligibility framework, and outcome structure of one of the pivotal trials.

Final Perspective

The RECONNECT trials studied a specific clinical-development question rather than peptide injections as a broad category.

They evaluated a characterized 1.75 mg subcutaneous bremelanotide product used as needed for 24 weeks in a narrowly defined population of premenopausal women with acquired, generalized HSDD.

Accurate interpretation keeps the desire and distress endpoints separate, includes safety and discontinuation data, distinguishes the controlled phase from the open-label extension, and avoids extending the findings to untested populations, routes, formulations, or products sold under the PT-141 name.